Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

JAVELIN Renal 101 trial: avelumab and axitinib for advanced renal cell carcinoma

ESMO 2018

19 - 23 Oct 2018

Published: 21 Oct 2018

Rating:

Save

Dr Robert J. Motzer - Memorial Sloan-Kettering Cancer Center, New York, USA

Dr Robert J. Motzer speaks at the ESMO 2018 congress about avelumab axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma.

To watch his interview with ecancer click here.

Related Videos

ASCO 2026: Latest updates in mRCC

Dr Toni Choueiri, Prof Viktor Grünwald, Dr Martin Voss and Prof Jens Bedke

30 May 2026

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou

19 Sep 2024

ESMO 2024: Optimising the personalisation of prostate cancer treatment

Prof Alison Birtle, Dr Alejo Rodríguez-Vida, Dr Pasquale Rescigno and Prof Gunhild von Amsberg

15 Sep 2024

EAU 2024: Bladder cancer latest

Dr Bernadett Szabados, Dr Félix Guerrero-Ramos, Dr Yohann Loriot, Prof Andrea Necchi and Dr Cosimo De Nunzio

9 Apr 2024

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini

25 Mar 2024

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

4 Aug 2023

mRCC: Atezolizumab after progression with prior ICI treatment shows no benefit and increases toxicity

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

5 Jun 2023

The current status of multiple myeloma diagnosis and treatment

Dr Patricio Duarte - Instituto Universitario CEMIC, Buenos Aires, Argentina

24 May 2023

JAVELIN Renal 101 trial: avelumab and axitinib for advanced renal cell carcinoma

ESMO 2018

Related Videos

More from ecancer